| Literature DB >> 33480202 |
Kyung Min Kim1, Soo Jin Cho2, Hye Jung Shin3, Kwang Ik Yang4, Daeyoung Kim5, Chang Ho Yun6, Min Kyung Chu7.
Abstract
BACKGROUND ANDEntities:
Keywords: disability evaluation; epidemiology; headache; migraine; prevalence
Year: 2021 PMID: 33480202 PMCID: PMC7840323 DOI: 10.3988/jcn.2021.17.1.77
Source DB: PubMed Journal: J Clin Neurol ISSN: 1738-6586 Impact factor: 3.077
Clinical characteristics of individuals with migraine in the 2009 Korean Headache Survey and the 2018 Korean Sleep-Headache Survey
| 2009 ( | 2018 ( | ||
|---|---|---|---|
| Age, years | 41.8±11.2 | 43.1±12.8 | 0.465 |
| Monthly headache frequency | 1.0 [0.4–4.0] | 0.8 [0.3–3.0] | 0.583 |
| Headache severity, VAS score | 6.0 [5.0–7.0] | 6.0 [5.0–7.0] | 0.747 |
| Headache intensity | |||
| Mild | 20 (22.0) | 19 (16.7) | 0.336* |
| Moderate | 58 (63.7) | 73 (64.0) | |
| Severe | 13 (14.3) | 22 (19.3) | |
| Unilateral location | 50 (54.9) | 78 (60.9) | 0.529 |
| Pulsating quality | 51 (56.0) | 89 (78.1) | 0.365 |
| Aggravation during routine physical activity | 62 (68.1) | 56 (49.1) | 0.005 |
| Nausea | 82 (90.1) | 102 (89.5) | 0.784 |
| Vomiting | 28 (30.8) | 52 (45.6) | 0.028 |
| Photophobia | 41 (45.1) | 44 (38.6) | 0.330 |
| Phonophobia | 54 (59.3) | 63 (55.3) | 0.737 |
| Osmophobia | 47 (51.6) | 45 (39.5) | 0.104 |
Data are mean±standard-deviation, median [interquartile range], or n (%) values.
*Comparison of the proportion with moderate-to-severe headache intensity, †Categorical variables were compared using linear regression analyses while adjusting for sex and age (in years, as a continuous variable), and numerical variables were compared using logistic regression analyses while adjusting for age and sex.
VAS: visual analogue scale.
Fig. 1Impact of headache as assessed using the HIT-6 among individuals with migraine in the 2009 Korean Headache Survey and the 2018 Korean Sleep-Headache Survey. HIT-6 scores: little to no impact, <50; some impact, 50–55; substantial impact, 56–59; severe impact, ≥60. HIT-6: Headache Impact Test-6.
Headache-related disability of individuals with migraine in the 2009 Korean Headache Survey and the 2018 Korean Sleep-Headache Survey
| 2009 ( | 2018 ( | ||
|---|---|---|---|
| Missed activity (days/3 months) | |||
| 0 | 80 (87.9) | 77 (67.5) | 0.001† |
| 1–2 | 5 (5.5) | 27 (23.7) | |
| 3–5 | 5 (5.5) | 5 (4.4) | |
| ≥6 | 0 (0.0) | 5 (4.4) | |
| No response | 1 (1.1) | 0 (0.0) | |
| Duration | 0.3±1.0 | 1.1±2.9 | 0.013* |
| Reduced productivity (days/3 months) | |||
| 0 | 67 (73.6) | 92 (80.7) | 0.228† |
| 1–2 | 11 (12.1) | 12 (10.5) | |
| 3–5 | 10 (11.0) | 8 (7.0) | |
| ≥6 | 0 (0.0) | 2 (1.8) | |
| No response | 3 (3.3) | 0 (0.0) | |
| Duration | 1.4±1.4 | 0.8±2.8 | 0.679* |
Data are n (%) or mean±standard-deviation values.
*Compared using linear regression analyses while adjusting for sex and age (in years, as a continuous variable), †Comparison of the proportion of having missed activity or fewer productivity days using logistic regression analyses while adjusting for age and sex, ‡Three individuals with migraine did not report the number of days with missed activity, and one individual with migraine did not report the number of days with reduced activity in the 2009 survey. All individuals with migraine reported the number of days with missed activity and reduced activity in the 2018 survey.
Headache treatment patterns among individuals with migraine in the 2009 Korean Headache Survey and the 2018 Korean Sleep-Headache Survey
| 2009 ( | 2018 ( | ||
|---|---|---|---|
| No treatment | 29 (33.0) | 30 (26.3) | 0.298 |
| OTC medications | 47 (50.0) | 62 (54.4) | 0.533 |
| Traditional Korean medical clinic | 3 (3.3) | 4 (3.5) | 1.000 |
| Alternative medicine | 0 (0.0) | 4 (3.5) | 0.131 |
| Clinics or hospitals | 17 (19.8) | 20 (17.5) | 0.682 |
Data are n (%) values.
OTC: over-the-counter.